Foster GR, et al. - During this research, the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) were comprehensively examined by the authors in compensated cirrhotic subjects with genotype (GT)3 infection. Findings displayed high efficacy in individuals with hepatitis C virus (HCV) GT3 infection and cirrhosis. It was observed that treatment beyond 12 weeks was not required, and efficacy was maintained despite baseline resistance-associated substitutions (RASs). Hence, the use of EBR/GZR plus SOF was suggested for 12 weeks without RBV for treatment-naive and peginterferon/RBV–experienced people with GT3 infection and cirrhosis.